Miloš Miljković

About

Dr. Miloš Miljković is the Chief Medical Officer at Cartesian Therapeutics in the United States. His research primarily focuses on innovative cellular therapies for autoimmune diseases, particularly in relation to T-cell lymphomas and B-cell maturation antigen-directed mRNA cell therapy. He has published extensively on topics such as the regulatory aspects of Paxlovid and the methodological challenges in classifying leukemic disorders, contributing significantly to advancing therapeutic strategies in hematological malignancies.